H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX)
On August 8, 2025, H.C. Wainwright reaffirmed its ‘Buy’ rating on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) with a $16 price target.
Amylyx Pharmaceuticals Inc. (AMLX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 8,800,000 | $56,408,000 | +55% | 0.1% |
| 2. | Perceptive Advisors Joseph Edelman | 7,902,365 | $50,654,160 | +1% | 1.88% |
| 3. | Point72 Asset Management Steve Cohen | 4,536,266 | $29,077,464 | +395% | 0.06% |
| 4. | Saturn V Capital Management Xiaoying Tian | 3,260,570 | $20,900,254 | +35% | 8.47% |
| 5. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,934,405 | $18,809,536 | 0.74% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.70 | 10,000 | $37,005.00 | 10,000 | 2025-03-20 | Filing | |
| $2.53 | 40,000 | $101,368.00 | 233,464 | 2024-09-12 | Filing | |
| $2.13 | 50,000 | $106,590.00 | 55,000 | 2024-09-05 | Filing | |
| $2.20 | 100,000 | $219,800.00 | 858,571 | 2024-09-03 | Filing | |
| $1.89 | 2,250 | $4,252.28 | 5,000 | 2024-05-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.01 | 200 | $3,002.00 | 3,325,301 | 2025-09-30 | Filing | |
| $14.37 | 29,775 | $427,950.12 | 3,325,501 | 2025-09-30 | Filing | |
| $14.58 | 8,828 | $128,668.98 | 148,141 | 2025-09-30 | Filing | |
| $14.65 | 10,558 | $154,650.42 | 280,430 | 2025-09-30 | Filing | |
| $15.00 | 200 | $2,999.50 | 3,325,347 | 2025-09-30 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,990 | $176,534 | 0% | |
| 2. | 501 | $6,809 | 0.01% | |
| 3. | 125 | $1,699 | 0% | |
| 4. | 64 | $870 | 0% | |
| 5. | 55 | $748 | 0% |
News See All
11 Best Single Digit Stocks to Buy According to Hedge Funds
The winning streak of U.S. stocks extended on Wednesday, August 13, 2025, with the S&P 500 and Nasdaq reaching fresh record highs for the second day in a row.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2025 Earnings Call Transcript August 7, 2025Amylyx Pharmaceuticals, Inc. misses on earnings expectations.
Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now.
13 Best Low Priced Pharma Stocks to Buy Now
On July 9, Afsaneh Beschloss, RockCreek Group founder & CEO, joined 'Closing Bell Overtime' on CNBC to talk about the latest round of tariff threats.
Amylyx Pharmaceuticals Gains FDA Fast Track for ALS Drug AMX0114
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best biotech stocks to invest in now. On June 3, Amylyx Pharmaceuticals announced that the US FDA granted Fast Track designation to AMX0114.
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2025 Earnings Call Transcript
Operator: Good morning, my name is Liane and I will be your conference operator today.
13 Best Biotech Penny Stocks to Buy According to Hedge Funds
Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas.
10 Hot Biotech Stocks Under $5
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
Hedge Fund Resource Center Billionaire Hedge Funds
